A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high‐risk pediatric patients

Abstract

Our study provides evidence that defibrotide prophylaxis is feasible in pediatric patients undergoing HSCT at high risk for TA-TMA and preliminary data indicating that defibrotide may reduce the risk of TA-TMA.